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Platelet Function Monitoring in
Patients With Coronary Artery Disease
Paul A. Gurbel, MD,* Richard C. Becker, MD,† Kenneth G. Mann, PHD,‡
Steven R. Steinhubl, MD,§ Alan D. Michelson, MD
Baltimore, Maryland; Durham, North Carolina; Burlington, Vermont; Lexington; Kentucky;
and Worcester, Massachusetts
Studies focused on patient responsiveness to antiplatelet therapies, particularly aspirin and clopidogrel, have
increased in recent years. However, the relations of in vivo platelet function and adverse clinical events to results
of ex vivo platelet function tests remain largely unknown. This article describes current methods of measuring
platelet function in various clinical and research situations and their advantages and disadvantages, reviews evi-
dence for antiplatelet response variability and resistance, discusses the potential pitfalls of monitoring platelet
function, and demonstrates emerging data supporting the positive clinical and treatment implications of platelet
function testing. (J Am Coll Cardiol 2007;50:1822–34) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.051s
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mhe rationale for a review article on platelet function
onitoring in patients with coronary artery disease is the
urrent intense controversy surrounding the clinical impor-
ance of non-responsiveness to antiplatelet therapy (1–5).
esponse variability and resistance to clopidogrel therapy
ere first reported in 2003 (6). Since then the number of
tudies focused on patient responsiveness to antiplatelet
herapies has increased substantially and now is the subject
f entire sessions at peer-reviewed international cardiovas-
ular meetings (7–28). Recent studies have suggested a
elation between high post-treatment platelet reactivity and
lopidogrel nonresponsiveness in patients undergoing per-
utaneous revascularization and increased ischemic events
ncluding stent thrombosis (12,13,17–28). Variable respon-
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ccepted July 31, 2007.iveness to clopidogrel has served as a rationale for the
evelopment of new P2Y12 inhibitors with superior phar-
acodynamic profiles (29). Similarly, nonresponsiveness to
spirin treatment and its relation to the occurrence of
dverse clinical events are also subjects of considerable
ontroversy in recent years (2–5,30–35). However, the
etermination of in vivo platelet function through ex vivo
esting has significant limitations (36).
This paper discusses the differences among methods used
o measure platelet function and activation, summarizes the
vidence for antiplatelet response variability, and examines
esearch studies reporting higher event rates in patients with
onresponsiveness to antiplatelet therapy by ex vivo testing.
urrent Clinical Tests of Platelet Function
he answer to “which is the right test of platelet function?”
an vary according to the purpose of testing. The first tests,
eveloped and used to screen patients for bleeding disorders,
ave since been used to diagnose specific conditions, from
he rare (Glanzmann thrombasthenia) to the common
storage-pool disease). More recently, platelet function
easurements have been used to assess the effects of
ro-hemostatic and antiplatelet therapies in clinical and
esearch settings. Finally, monitoring of platelet function
an be useful in the practice of transfusion medicine. In each
f these situations, a different platelet function test might
ave particular applicability.
For patients with coronary artery disease (CAD), the
otential utility of measuring platelet function includes
onitoring antiplatelet therapy and predicting clinical out-omes. For example, although aspirin reduces the risk of
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November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomeshrombotic events in high-risk patients by approximately 25%,
0% to 20% of treated patients will have another thrombotic
vent during long-term follow-up (37). These patients might
equire additional platelet-directed therapy with clopidogrel
r other agents. A key question relating to this issue is
hether standardized laboratory tests assessing the plate-
et response to aspirin or clopidogrel can predict clinical
resistance.”
ethods of Measuring Platelet Function
ggregation. Table 1 and Figures 1 and 2 summarize the
rinciples and characteristics of the most commonly used
latelet-function tests. The historical “gold standard” test is
ight transmittance aggregometry (turbidimetric) (LTA),
hich is based on the stimulation of platelet–platelet aggrega-
ion in platelet-rich plasma after stimulation with various
gonists. Figure 3 shows the intersubject variability in platelet
ggregation stimulated by commonly employed agonists (38).
ight transmittance aggregometry has been the most widely
sed technique to monitor the effects of antiplatelet agents,
ncluding aspirin, clopidogrel, other P2Y12 inhibitors, and
latelet glycoprotein (GP) IIb/IIIa inhibitors (36). Potential
isadvantages include the requirement for immediate process-
ng, variable reproducibility, large required sample volumes,
engthy processing time, and expenses of the aggregometer and
rained operators. Light transmittance aggregometry has also
een the most widely investigated method to predict clinical
utcomes (33). Impedance aggregometry is conceptually sim-
lar to LTA, but it uses whole blood instead of platelet-rich
lasma and aggregation is measured by impedance, not light
ransmittance (39).
eceptor expression. The resting and stimulated expres-
ion of activation-dependent receptors can be quantified by
ow cytometry with monoclonal antibodies (Fig. 1) (36).
his technique has been particularly useful to assess phar-
acologic effects. The most widely studied receptors in-
lude P-selectin and GP IIb/IIIa. Platelet–leukocyte aggre-
ates also have been measured as a marker of platelet
ctivation, and they have been proposed as a more stable
easure of acute coronary syndromes (ACS) compared with
-selectin (40). Less information is available correlating
easurement of receptor expression and clinical outcomes.
ajor limitations are the complexity of the technique,
hich requires an experienced laboratory staff, and the
esultant high costs.
ntracellular signaling. The coupling of P2Y12 to the
nhibition of adenylate cyclase by an inhibitory G protein
as been exploited to measure reactivity of the receptor in
he presence of P2Y12 inhibitors (Fig. 2) (41). Vasodilator-
timulated phosphoprotein (VASP) is phosphorylated by
rotein kinases that are activated by cyclic adenosine mono-
hosphate. With flow cytometry and methods to make the
latelet membrane permeable, it is possible to quantify the
mount of phosphorylated VASP by monoclonal antibodies
s a measure of unblocked P2Y12 (41). Advantages include ihe specificity for the P2Y12 sig-
aling pathway and the stability
f the method compared with
ggregometry.
oint-of-careassays. The Verify-
ow method (Accumetrics, San
iego, California) uses arachi-
onic acid, adenosine diphosphate
ADP), or thrombin receptor-
ctivating peptide (TRAP) to as-
ess platelet responsiveness to aspi-
in, P2Y12 inhibitors, or GP IIb/
IIa inhibitors, respectively (42).
he technique measures platelet
ggregation with fibrinogen-
oated beads and has been used to
redict outcomes in patients un-
ergoing percutaneous coronary
ntervention (PCI). Advantages of
he VerifyNow include its ease of
se and correlation with turbidi-
etric aggregometry. In the thrombelastogram (TEG)
lateletMapping technique (Haemoscope Corporation, Niles,
llinois), the contribution of arachidonic acid-induced platelet
ggregation and ADP-induced aggregation to the overall
ensile strength of a platelet–fibrin clot can be quantified and
orrelated with turbidimetric aggregometry (23). The prepara-
ion of samples for thrombelastography is more complex than
hat for VerifyNow, but thrombelastography can provide co-
gulation measurements not possible with VerifyNow.
latelet-released factors. The most widely measured fac-
ors are shown in Table 1 (36). Serum thromboxane B2 and
rinary 11-dehydro-thromboxane B2 have been used to
ssess responsiveness to aspirin and to predict outcomes in
spirin-treated patients. Elevated soluble CD40 ligand and
-selectin have been observed in ACS, and at least 1 study
valuated the diagnostic utility of soluble P-selectin as a
arker of myocardial infarction (MI) (43). All of the soluble
arkers are measured by immunoassays; limitations in their
tility include their presence in extraplatelet sources.
ntiplatelet Response
ariability or “Resistance”
efinition. Multiple signaling pathways mediate platelet
ctivation and the occurrence of thrombotic events. Thus a
reatment strategy directed against a single pathway cannot
e expected to prevent the occurrence of all events (29).
ecause thrombosis results from multiple signaling path-
ays, treatment failure alone is not sufficient evidence of
rug “resistance.” The optimal definition of “resistance” or
onresponsiveness to an antiplatelet agent might be evi-
ence of persistent activity of the specific target of the
ntiplatelet agent (29). Because the active metabolite of
lopidogrel irreversibly inhibits the P2Y12 receptor by form-
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CAD  coronary artery
disease
COX  cyclooxygenase
GP  glycoprotein
INR  international
normalized ratio
LTA  light transmittance
aggregometry
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
VASP  vasodilator-
stimulated phosphoproteinng a covalent disulfide bond, there would be evidence of
CA
¶
p
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Table 1 Current Clinical Tests of Platelet Function
Advantages Drawbacks
Predicts
Outcomes?
Able to Monitor
Aspirin Thienopyridines
GP IIb/IIIa
Inhibitors
Cessation of Blood Flow by Platelet Plug (for PFA, at High Shear)
Bleeding time In vivo; physiological Nonspecific; not sensitive; scarring; high
interoperator CV
No No No No
PFA-100 Simple; rapid; small sample
volume; no preparation; whole-
blood assay
No instrument adjustment; depends on
vWF, Hct
Yes Yes NR NR
Platelet–Platelet Aggregation
Platelet aggregometry:
turbidimetric
Historical “gold standard” Variable reproducibility; expensive; large
sample volume; sample preparation;
time-consuming
Yes Yes*† Yes
Platelet aggregometry:
impedance
Whole-blood assay Expensive; large sample volume; sample
preparation; time-consuming
Yes Yes* Yes† Yes
VerifyNow Simple; rapid; POC; small sample
volume; no sample
preparation; whole-blood assay
No instrument adjustment Yes Yes‡ Yes§ Yes
Plateletworks Little sample preparation; whole-
blood assay
Not well studied No Yes* Yes† Yes
Shear-Induced Platelet Adhesion
Impact cone and plate(let)
analyzer
Simple; rapid; POC; small sample
volume; high shear; whole-
blood assay
Not widely available No Yes* Yes† NR
Platelet Contribution to Clot Shear Elasticity
Thrombelastogram POC; whole-blood assay; platelet–
fibrin clot formation and clot
lysis data
Limited studies Yes Yes* Yes† Yes
Basis: Activation-Dependent Changes in Platelet Surface
Platelet surface P-selectin,
platelet surface
activated GP IIb/IIIa,
leukocyte–platelet
aggregates
Low sample volume; whole-blood
assay
Sample preparation; expensive; requires
flow cytometer, experienced staff
Yes Yes* Yes† Yes
Activation-Dependent Signaling
VASP phosphorylation Low sample volume; whole-blood
assay; P2Y12–dependent
Sample preparation; expensive; requires
flow cytometer, experienced staff
Yes No Yes No
Activation-Dependent Release From Platelets
Platelet-derived
microparticles
Low sample volume; whole-blood
assay
Sample preparation; expensive; requires
flow cytometer, experienced staff
No No No No
Serum thromboxane B2 COX-1–dependent Indirect; not platelet-specific No Yes No No
Urinary 11-dehydro
thromboxane B2
COX-1–dependent indirect; not platelet-specific; depends
on renal function
Yes Yes No No
Plasma-soluble CD40
ligand
Most CD40 ligand is platelet-
derived
Plasma separation can cause artifactual
platelet activation
Yes No No No
Plasma GP V Platelet-specific Plasma separation can cause artifactual
platelet activation; reflects only
thrombin-mediated platelet activation
No No No No
-granule constituents¶ Reflect platelet secretion Plasma separation can cause artifactual
platelet activation; endothelial cells
also secrete P-selectin
No No No No
dapted from Michelson et al. (2). *With arachidonic acid. †With adenosine diphosphate. ‡With aspirin cartridge. §With P2Y12 cartridge. With thrombin receptor-activating peptide (TRAP) cartridge.
Platelet factor 4, -thromboglobulin, soluble P-selectin.
COX cyclooxygenase; CV coefficient of variation; GP glycoprotein; Hct hematocrit; NR not recommended; PFA Platelet Function Analyzer; POC point of care; VASP vasodilator-stimulated
hosphoprotein; vWF  von Willebrand factor.
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November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomesost-treatment P2Y12 reactivity in nonresponsive patients.
or aspirin, the identification of resistance would use a
aboratory technique that detects residual activity of cyclo-
xygenase (COX)-1. Antiplatelet response variability and
esistance and their proposed mechanisms have been de-
cribed in previous publications (1–5,29).
spirin. Aspirin acetylates a serine moiety present in
OX-1, resulting in irreversible inhibition (36). Laboratory
Figure 1 Laboratory Assessment of Aspirin Responsiveness
Arachidonic acid (AA) stimulation of platelet aggregation depends directly on cycloo
measurement of stable metabolites via enzyme-linked immunoassays. Adenosine
ods. Aggregation occurs through COX-1–independent and –dependent pathways af
protein; LTA  light transmittance aggregometry; PFA  platelet function analyzer;
Figure 2 Laboratory Assessment of Clopidogrel Responsivenes
Adenosine diphosphate (ADP) stimulates 2 distinct receptors (P2Y1 and P2Y12) th
sured by: (A) receptor reactivity; intracellular signaling downstream from the P2Y1
stimulated phosphoprotein (VASP) with monoclonal antibodies (Y); the P2Y12 is co
dependent receptor expression (active glycoprotein [GP] IIb/IIIa and P-selectin) ide
light transmittance aggregometry (LTA), aggregation of platelets with fibrinogen-coa
platelet–fibrin clot strength by thrombelastography.ethods for assessing platelet responsiveness to aspirin can be
ategorized as COX-1–specific and COX-1–nonspecific (Fig.
). The COX-1–specific methods include arachidonic acid-
nduced platelet aggregation measured by LTA, thrombelas-
ography with the PlateletMapping assay, and VerifyNow and
nzyme-linked immunoassay determination of the stable me-
abolites of thromboxane A2 in serum or in urine. The
OX-1–nonspecific methods include ADP- or collagen-
ase (COX)-1 activity. In vivo production of thromboxane A2 (TxA2) is assessed by
phate (ADP)- and collagen-stimulated aggregation are COX-1–nonspecific meth-
ulation by the latter agonists. ASA  acetylsalicylic acid (aspirin); GP  glyco-
 phospholipase A2; PRP  platelet-rich plasma; TEG  thrombelastography.
linked to specific signaling pathways (dashed arrows). Response can be mea-
tor is measured by flow cytometry that assesses phosphorylation of vasodilator-
by a Gi protein to adenylyl cyclase; PKA  protein kinase A; (B) activation-
by monoclonal antibodies (Y) with flow cytometry; (C) aggregation determined by
ads (VerifyNow), or measuring the contribution of platelet aggregation to totalxygen
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Platelet Function Versus Clinical Outcomes November 6, 2007:1822–34nduced platelet aggregation as determined by LTA or the
latelet Function Analyzer (PFA)-100 (Dade-Behring, Mi-
mi, Florida) (36).
Aspirin resistance is infrequent among patients undergo-
ng elective PCI who are treated with 325 mg daily as
ssessed by arachidonic acid-induced platelet aggregation
ith LTA (44,45). In a recent randomized, double-blind,
ouble-crossover investigation of aspirin dosing (81 to 325
g) in patients with stable CAD, at any 1 dose, 0% to 6%
ere aspirin-resistant by COX-1–specific methods and 1%
o 27% were resistant according to COX-1–nonspecific
ethods (46). Moreover, there was no consistency in the
easurement of aspirin responsiveness between point-of-
ervice assays in these patients receiving different doses of
spirin. Thus the incidence of aspirin resistance seems to be
ighly assay-dependent and is rare when determined by
ethods that directly indicate the activity of COX-1
46,47). Treatment noncompliance can also affect the iden-
ification of aspirin “resistance” (44,45).
Aspirin resistance also might be associated with concom-
tant clopidogrel “resistance” (13,48). Patients identified as
spirin- and clopidogrel-resistant have exhibited high plate-
et reactivity to collagen in addition to ADP and arachidonic
cid stimulation (13,49). The latter studies suggest a gen-
ralized high-platelet-reactivity phenotype that might be
ssociated with an increased risk for ischemic events.
lopidogrel. The detection of nonresponsiveness to clopi-
Figure 3 Distribution of Aggregation Response
to Submaximal Agonist Concentrations
Intersubject variation in platelet aggregation in response to various agonists in
citrate-anticoagulated samples. ADP  adenosine diphosphate; CRP  collag-
en-related peptide. Reprinted from Yee et al. (38), with permission.ogrel has been most widely based on LTA studies using tDP as an agonist (6,8–24,26,36). Flow cytometric mea-
urement of activation-dependent receptor expression after
DP stimulation, point-of-care assays, and VASP phos-
horylation have also been used to detect nonresponsiveness
Table 1, Fig. 2) (6,20–23,25–28).
In our early investigations of the antiplatelet effect of
lopidogrel and aspirin therapy in patients undergoing
oronary stenting we observed overall modest inhibition of
mol/l ADP-included aggregation and large variability in
he response (6,50). We defined resistance as an absolute
hange in aggregation (A) 10%. Thus, in our definition
e did not normalize for baseline aggregation as has been
one by other investigators (Table 2). Müller et al. (8)
efined nonresponsiveness as a relative change in aggrega-
ion 10%. In the first study by our group reporting
lopidogrel resistance, patients undergoing PCI received a
00-mg loading dose of clopidogrel, and platelet function
as measured serially after stenting (6). This study reported
normal distribution of A, and some patients had no
emonstrable antiplatelet effect by LTA measurements over
he next 24 h (Fig. 4) (6). The representation of the
esponse profile as depicted in Figure 4 precisely describes
he antiplatelet effects in an entire study population (50) and
as been subsequently used by other investigators to provide
urther evidence of clopidogrel response variability (51).
The response to clopidogrel has been most studied in
atients undergoing PCI (Table 2), and numerous studies
ave reported wide variations in response to therapy and
ates of nonresponse of 5% to 44% (6–19). Measurement of
ASP phosphorylation has also shown high residual reac-
ivity of the P2Y12 receptor in selected patients treated with
lopidogrel (52). Differences in the prevalence of resistance
etween studies might be related to differences in dosing,
ifferences in definitions (e.g., measurement of relative
hange in aggregation versus absolute change in aggrega-
ion, measurement of maximum versus late aggregation),
aboratory methods, or insufficient time allowed before
lood sampling to detect a maximum effect (Table 2).
lopidogrel response variability has multiple proposed eti-
logies and has been reviewed by the authors in prior
ublications (1,2,29).
itfalls in Monitoring Platelet Function
basic problem with attempting to measure platelet func-
ion or drug-related inhibition, let alone correlating it with
linical outcomes, is that no single test encompasses the
omplexity of platelet biology and function (Fig. 5) (29,36).
fter plaque rupture or endothelial denudation, platelets
dhere to von Willebrand factor and collagen and then are
xposed to tissue factor-generated thrombin. Platelet sig-
aling pathways become activated, with transmission of
nformation through G-protein–coupled pathways to the
ytoskeleton, leading to platelet secretion. Aggregation is
nitiated through binding of fibrinogen and other ligands to
he activated GP IIb/IIIa receptor. Platelets also secrete
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November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomesicroparticles that play a multifaceted role in inflammation
nd tissue-factor release processes from leukocytes. Finally,
oagulation factors are assembled on the surface of activated
latelets and are inhibited by endogenous anticoagulant
athways. No single test of platelet function can capture all
f these distinct yet integrated biological events. The
leeding time might be considered a test of platelet aggre-
ate formation and primary hemostasis, but this test varies
reatly among individuals, is not specific or sensitive for
rug- or disease-related effects, and is highly subject to
echnical and operator influences (53).
hoice of anticoagulant. Citrate, a widely used anticoag-
lant for collecting blood samples, was introduced in 1902
s a way to identify the importance of ionized calcium in the
oagulation–protein reaction system. The use of citrate
nticoagulation, however, can sequester calcium, confound-
ng the ability to assess interindividual pharmacodynamic
esponses and variability in platelet aggregation. Figure 3
hows intersubject variability in response to ADP, collagen,
istocetin, and collagen-reactive peptide agonists (38). At
east some of this heterogeneity reflects differences in citrate
oncentrations among samples (due to differing volumes
lopidogrel Response Variability/Resistance Studies
Table 2 Clopidogrel Response Variability/Resistance Studies
Study (Ref. #) n Patients
Clopidogrel Dose
Load/qd
Gurbel et al. (6) 92 PCI 300/75
Jaremo et al. (7) 18 PCI 300/75
Müller et al. (8) 119 PCI 600/75
Mobley et al. (9) 50 PCI 300/75
Lepantalo et al. (10) 50 PCI 300/75
Angiolillo et al. (11) 48 PCI 300/75
Matetzky et al. (12) 60 PCI 300/75
Lev et al. (13) 150 PCI 300
Angiolillo et al. (14) 52 Diabetics nondiabetics/
CAD and PCI
300
Gurbel et al. (15) 190 PCI 300 or 600/7
Dziewierz et al. (16) 31 CAD 300
Geisler et al. (17) 379 PCI 600
Buonamici et al. (19) 804 PCI 600
DP adenosine diphosphate; CAD coronary artery disease; CPA cone and platelet analyzer;
unction Analyzer-100; PW  Plateletworks; TEG  thrombelastography.ollected), but how much reflects the anticoagulant versus che individual is unknown. Expression of P-selectin on the
latelet surface is likewise increased by citrate anticoagula-
ion of samples versus other anticoagulants (54).
One study compared the effects of citrate and a nonch-
lating anticoagulant, D-phenylalanyl-prolyl-arginine chlo-
omethyl ketone (PPACK), on ex vivo platelet aggregation
esting within a multicenter study of the GP IIb/IIIa
nhibitor eptifibatide in patients with ACS (55). At all time
oints measured after eptifibatide administration, inhibition
f platelet aggregation in response to ADP stimulation was
reater for citrate- versus PPACK-anticoagulated samples.
abarthe et al. (56) measured clopidogrel responsiveness in
2 patients and 20 control subjects with both citrate- and
PACK-anticoagulated samples. They noted that clopi-
ogrel responsiveness might be more accurately reflected
hen using PPACK as the anticoagulant. They also sug-
ested that measurement of final aggregation, which in-
ludes platelet disaggregation, might be a better measure-
ent of clopidogrel nonresponsiveness than measurement
f maximum ADP-induced aggregation. In contrast, in a
ecent study of 100 patients undergoing PCI with stenting
ho received either a 300- or 600-mg loading dose of
Definition of Clopidogrel
Resistance Time Incidence
10% absolute change in ADP-LTA 24 h 31%–35%
ADP-induced fibrinogen binding
40% of baseline
24 h 28%
5 and 20 mol/l ADP-induced
aggregation, 10% relative
change
4 h 5%–11%
1 mol/l ADP-induced aggregation,
TEG and Ichor PW, 10%
absolute inhibition
Pre and post 30%
5 mol/l ADP-induced aggregation
and PFA-100, 10% inhibition
and 170 s
2.5 h 40%
6 mol/l ADP-induced aggregation,
40% relative inhibition
10 min, 4 h, 24 h 44%
5 mol/l ADP-induced aggregation
and CPA, 4th quartile inhibition
Daily for 5 days 25%
5 mol/l ADP-induced aggregation,
10% absolute change
20–24 h 24%
10% relative inhibition 24 h 38%/8%
5 and 20 mol/l ADP-induced
aggregation, 10% absolute
inhibition
24 h 28%–32%/8%
20 mol/l ADP-induced
aggregation, 10% absolute
change
24 h 23%
20 mol/l ADP-induced
aggregation, 30% absolute
inhibition
6 h 6%
10 mol/l ADP-induced
aggregation, 70% post-
treatment aggregation
12–18 h 13%
light transmittance aggregometry; PCI percutaneous coronary intervention; PFA-100 Platelet(mg),
5lopidogrel, final aggregation and maximum aggregation were
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Platelet Function Versus Clinical Outcomes November 6, 2007:1822–34ffected to the same degree in nonresponsive patients (57).
hus, these measurements in the latter study seemed
ssentially equivalent in determining the prevalence of
onresponsiveness.
hoice of agonist. The choice and concentration of ago-
ist also have major implications for platelet function
Figure 4 Response Variability to Clopidogrel
Presentation of platelet function data as a histogram of the absolute change in
aggregation (A) in response to 5 mol/l adenosine diphosphate (ADP) stimu-
lation at 2 h after treatment with 300-mg clopidogrel loading dose. The A is
defined as baseline aggregation (%) minus the post-stent aggregation (%) and
is divided into deciles. Nonresponsiveness or resistance is defined as A
10%. Nonresponsiveness is present in those patients below the solid arrow.
Heightened post-treatment reactivity is present in those patients below the
dashed arrow. The curve represents a normal distribution of data (Statistica
software, Tulsa, Oklahoma). Adapted from Gurbel et al. (50), with permission.
Figure 5 Relation of Platelets, Plaque Rupture, Thrombus Form
Platelets mediate an array of in vivo processes leading to adverse events. Initial a
thrombin). The activated platelet surface is the site of coagulation-factor generatio
(adenosine diphosphate [ADP], TxA ) upon activation amplifies aggregation. PLT  pla2easurement. When assessing platelet response to aspirin,
or example, the focus should be primarily on inhibition of
spirin’s primary target, the COX-1 pathway; thus arachi-
onic acid is the most appropriate agonist. If the agonist
timulates multiple pathways leading to platelet activation,
hen the “response” to aspirin might be underestimated
ompared with methods using arachidonic acid. For clopi-
ogrel, this construct translates to measuring ADP-induced
esponses. Because ADP interacts with at least 2 receptors
n the platelet surface, P2Y12 and P2Y1, platelet function
ests will determine the combined biological effects of ADP
n these receptors. Assessment of clopidogrel’s effects on
2Y12 might be most accurately determined by measures of
ntracellular signaling events downstream from the receptor
e.g., quantification of VASP phosphorylation) (41).
ffect of thrombin and platelet count. Studies with
onchelating anticoagulants have delineated the importance
f thrombin’s activation of platelets in clotting, particularly
hrough the G-coupled protease-activated receptor (PAR)-1
athway. When whole blood is anticoagulated with corn
rypsin inhibitor and tissue factor is added, platelet activation
reflected by osteonectin secretion) generally precedes throm-
in generation (58). In fact, this reaction begins with 1% of
he amount of thrombin ultimately produced. Thus platelets
re particularly sensitive to thrombin-mediated activation, and
hrombin generation provides the receptor sites for factors Xa,
a, VIIIa, and IXa, which leads to the expression of most of
he thrombin in the reaction system.
Platelet counts also can influence the clotting time and
ggregation measured in platelet-rich plasma. In a study of
ealthy volunteers and individuals receiving chemotherapy,
latelet counts as low as 50,000 mm3 influenced clotting times
n a system using corn trypsin inhibitor-anticoagulated samples
nd tissue factor agonist (59). The same effect was observed in
, and Adverse Clinical Outcomes
on is stimulated by key primary agonists (collagen, von Willebrand factor [vWF],
ing to amplification of thrombin generation. Release of key secondary agonists
F  tissue factor; WBC  white blood cell; other abbreviations as in Figure 1.ation
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November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomeseasurement of total thrombin generation, at platelet
ounts 100,000 mm3. Furthermore, if the number of
latelets in the system was increased, clotting times and
hrombin generation returned to normal ranges. Adjusting
he platelet count in platelet-rich plasma with autologous
latelet-poor plasma has been recommended for platelet
ggregation studies. However, a recent study suggested that
djusting platelet counts before aggregation might affect the
nal platelet aggregation measurements by causing artifac-
ual inhibition (60).
Aspirin treatment does not attenuate thrombin genera-
ion substantially in whole blood. In fact, samples from
ome individuals taking aspirin have shown heightened
hrombin generation when stimulated with tissue factor
61). In contrast, when sampling blood escaping from a
icrovascular wound in the forearm, thrombin generation
as suppressed after administration of aspirin (62). The
ame individuals showed no suppression of thrombin gen-
ration in whole blood when tissue factor was added. Thus
spirin seems to affect alternative and/or complementary
athways to the tissue-factor–mediated process after micro-
ascular trauma.
Glycoprotein IIb/IIIa inhibitors also have been tested in
he corn trypsin inhibitor–tissue factor model of coagula-
ion. At lower concentrations of the reagents, abciximab and
ptifibatide depress thrombin generation (61). At high
oncentrations, however, this effect is undetectable; it is
asked by the overall kinetics of the reaction system.
imilar findings have been reported when performing the
igh-concentration experiment in the presence of prosta-
landin E1 (61). Thus the ability to detect drug-related
ntiplatelet activity depends greatly on the intensity of
timulation used in in vitro models.
No single test can encompass or reflect all aspects of
latelet biology. Moreover, the choice of anticoagulant for
ampling and agonist can influence test results. Inherent
eterogeneity in platelet performance even under normal
ircumstances creates challenges when attempting to mea-
ure treatment responses. Measurement tools and defini-
ions for normal/abnormal responsiveness to platelet-
irected therapy must be carefully constructed to reflect
eceptor signaling and pathway specificity. Population-
ased and mechanistic studies, performed in parallel with
rials, registries, and/or research networks assessing clinical
utcomes, are required to answer several basic questions,
dvance the field, and foster patient-specific therapy.
orrelating Measures of
nterindividual Variability in
latelet Function With Clinical Outcomes
tudies attempting to correlate measures of platelet func-
ion—and its attenuation with drug therapies—with clinical
utcomes have often focused on a receptor-signaling path-
ay or reaction (activation or aggregation). Most com-
only, platelet function has been measured by the degree of hggregation in response to a specific concentration of
gonist, but platelet-fibrin interactions also have been mea-
ured, as have platelet activation via measures of platelet and
oluble P-selectin, urinary thromboxane metabolites, and
ther markers. These measures have been used primarily to
ssess relationships between platelet function and stent
hrombosis or major adverse cardiac events (MACE).
The number of patients studied within investigations
esigned to link ex vivo response variability to clinical
esistance is small overall, and there has been an absence of
erial measurements (12,13,17–28,30–35). Although some
tudies support a link between laboratory-based and clinical
resistance,” none has been definitive. In addition and more
mportantly, no published study has examined whether
ailoring therapy according to laboratory findings of aspirin
r clopidogrel resistance can improve clinical outcomes.
The International Society on Thrombosis and Haemo-
tasis Working Group on Aspirin Resistance (63) has
ecently stated that a clinically meaningful definition of
esistance should be based on data linking therapy-
ependent laboratory tests to clinical outcomes. The group
lso noted that the correct treatment, if any, of antiplatelet-
herapy resistance is unknown, given that no study has
ddressed the clinical effectiveness of altering therapy spe-
ifically on the basis of laboratory findings of resistance.
ther than within clinical trials, which the group encour-
ged, it is currently not appropriate to test patients for
spirin or clopidogrel resistance or to change therapy on the
asis of such testing.
A clinical trial designed to investigate antiplatelet resis-
ance would require sufficient power to answer 2 key
uestions: 1) which simple, inexpensive, and rapid test of
latelet function (or combination of tests) best predicts
linical outcomes of antiplatelet therapy for specific individ-
als with specific indications for treatment; and 2) are
ndividual outcomes improved when treatment is changed
n response to the test(s) results? A basic objective is to
evelop absolute or relative thresholds (upper and lower) for
est results, similar to the practice of tailoring warfarin
herapy according to a standardized international normal-
zed ratio (INR). The landscape for developing an equiva-
ent testing strategy for platelet-directed therapy is consid-
rably more complex with the concomitant use of several
rugs with different mechanisms of action and multiple
esting platforms.
Clinical trials also must investigate, in patients with
nown resistance and/or drug failure, the potential benefit
f dose adjustment or supplementary treatments with dif-
erent pharmacodynamic profiles. For example, if a patient
ith CAD suffers an event while already taking aspirin, it
ight be more effective to increase the dose of aspirin, add
thienopyridine agent for additional secondary prevention,
r both rather than simply substituting drugs.
elation of platelet reactivity to outcomes of aspirin
herapy. Early studies (30,31) suggested a relation between
igh platelet reactivity among patients receiving aspirin and
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Platelet Function Versus Clinical Outcomes November 6, 2007:1822–34n increased risk of vascular events (Table 3). In patients
nrolled in the HOPE (Heart Outcome Prevention Evalu-
tion) trial, Eikelboom et al. (32) showed a relation between
igh urinary 11-dehydro thromboxane B2 levels, a measure
f platelet thromboxane A2 generation, and the risk for
ubsequent ischemic events. Chen et al. (35) showed a
elation between high platelet reactivity measured by
ltegra Rapid Platelet Function Assay-ASA (Accumetrics)
nd periprocedural myonecrosis in patients undergoing
CI.
With LTA, Gum et al. (33,34) assessed the relation
etween aspirin resistance and the composite outcome of
eath, MI, or stroke over a mean 1.8 years of follow-up in
26 patients with stable CAD taking 325 mg of aspirin for
1 week before enrollment. In all, 5.2% of patients were
onsidered aspirin-resistant (70% mean aggregation in
esponse to 10 mol/l ADP and 20% aggregation after
ncubation with 0.5 mmol/l arachidonic acid). During
ollow-up, 24% of aspirin-resistant patients had an event
ersus 10% of nonresistant patients (p  0.03), but the
elationships between aspirin resistance (as a categorical or
ontinuous variable) and the component clinical events were
ot statistically significant. After adjustment for several risk
actors, aspirin resistance was an independent predictor of
ong-term adverse events.
With the PFA-100 analyzer to measure aspirin-mediated
latelet inhibition, several studies have reported increased
vent rates in patients with a profile of aspirin resistance
64,65). This method has several limitations, however,
ncluding poor correlation to other measures of platelet
erformance and dependence on von Willebrand factor level
nd activity and platelet count. The PFA-100 method also
ses collagen and epinephrine as agonists, neither of which
s specific for COX-1 activity, the target of aspirin. A major
imitation of all published studies of aspirin resistance is a
ack of serial platelet function measurements, particularly
ecause the degree of aspirin resistance can fluctuate over
ime and can be affected by aspirin dose (46,66).
elation of clopidogrel responsiveness/high post-treatment
latelet reactivity to clinical outcomes. Published studies
nvestigating the association between platelet reactivity to
DP (indicative of clopidogrel responsiveness) and the
ccurrence of ischemic events have involved patients under-
oing PCI, with most employing LTA measurement of
latelet function (Table 4) (12,13,17–24,26). These gener-
elation of Aspirin Responsiveness to Clinical Outcomes
Table 3 Relation of Aspirin Responsiveness to Clinical Outcom
Study (Ref. #) n Patients
Mueller et al. (31) 100 PVD Platele
Eikelboom et al. (32) 976 High-risk CAD Urinary
Gum et al. (33,34) 325 Stable CAD Light t
Chen et al. (35) 151 PCI RPFA
Grotemeyer et al. (30) 180 Post-CVA PlateleAD coronary artery disease; CVA cerebrovascular accident; MImyocardial infarction; PCI percu
nalyzer; Tx  thromboxane.lly small populations have reported links between
lopidogrel-induced platelet inhibition, post-treatment
latelet reactivity, periprocedural myonecrosis, stent throm-
osis, and recurrent ischemic events.
Matetzky et al. (12) examined 60 consecutive patients
ith MI undergoing primary PCI with stenting, all of
hom received clopidogrel, aspirin, and eptifibatide. Ten
onsecutive patients undergoing primary angioplasty with-
ut stenting and given no clopidogrel were the control
ubjects. Platelet aggregation was determined by LTA in
esponse to 5 mol/l ADP and 10 mol/l epinephrine and
y cone and plate(let) analysis expressed as the percent
urface coverage by platelets and average size of surface-
ound aggregates. When treated patients were grouped into
uartiles by percent reduction in ADP-induced aggregation
t day 6 versus baseline (before clopidogrel administration),
he responses varied from a mean aggregation of 103% of
he baseline value in the first quartile (considered
lopidogrel-resistant) to only 33% of the baseline value in
he fourth quartile (p 0.01 across groups). This variability
ersisted for epinephrine-induced aggregation and aggre-
ate size measurements. Over 6-month follow-up, 7 of the
major cardiac events occurred in the clopidogrel-resistant
roup; 40% of the first-quartile patients had another isch-
mic event. No correlation between platelet inhibition
easured by the cone and plate(let) device and clinical
utcomes was reported.
In the CLEAR-PLATELETS (Clopidogrel Loading
ith Eptifibatide to Arrest the Reactivity of Platelets)
tudy, ADP-induced aggregation was measured serially over
8 to 24 h in 120 patients undergoing stenting treated with
00 or 600 mg of clopidogrel. Fifty percent of these patients
ere randomized to treatment with eptifibatide (21). Pa-
ients with MI according to creatine kinase-MB release had
ignificantly greater mean platelet reactivity to ADP com-
ared with patients without MI (Fig. 6), suggesting a
hreshold of mean platelet aggregation that might be used as
reference point for future studies.
The relation of platelet reactivity and stent thrombosis
as also been investigated with most studies reporting that
igh post-treatment platelet activity as determined by var-
ous methods is associated with stent thrombosis (19,25–
8). However, the reported measures varied widely in
atients with and without thrombosis. Further studies lend
trong support to the association between high post-
Method Results
egation (whole blood) 87% increase in reocclusion
hydro TxB2 Increase in MI/stroke/death with increased TxB2
ittance aggregometry 3.12-fold increase in MI/stroke/death
2.9-fold increase in myocardial necrosis
egates 10-fold increase in vascular eventses
t aggr
11-de
ransm
t aggrtaneous coronary intervention; PVD peripheral vascular disease; RPFA rapid platelet function
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November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomesreatment platelet reactivity to ADP and the occurrence of
ost-stenting ischemic events. Hochholzer et al. (18) stud-
ed 802 patients undergoing stenting treated with 600 mg
lopidogrel and found that patients with post-treatment
latelet aggregation above the median level had a 6.7-fold
ncrease in the risk of 30-day MACE. In another study of
04 patients undergoing stenting, Buonamici et al. (19)
emonstrated that stent thrombosis was more prevalent in
Figure 6 Evidence of a Possible Threshold
for Ischemic Events After Elective Stenting
Relation between creatine kinase-MB (CKMB) release and mean platelet aggre-
gation in response to 5 mol/l adenosine diphosphate measured serially over
18 to 24 h in patients undergoing stenting in the CLEAR PLATELETS study.
Adapted from Gurbel et al. (21) with permission. NL  normal limit; ULN 
upper limit of normal.
elation of Platelet Reactivity to ADP/Clopidogrel Nonresponsiven
Table 4 Relation of Platelet Reactivity to ADP/Clopidogrel Non
Study (Ref. #) n
Matetzky et al. (12) 60 Clopidogrel nonrespo
with clopidogrel
Geisler et al. (17) 379 1 Pre-procedural pla
loaded with clopid
Gurbel et al. (20) 192 1 Post-procedural pl
with clopidogrel at
Gurbel et al. (21,22) 120 1 Periprocedural me
loaded with clopid
eptifibatide
Bliden et al. (23) 100 1 Pre-procedural pla
maintenance clop
Cuisset et al. (24) 106 1 Pre-procedural pla
patients treated w
Lev et al. (13) 120 Clopidogrel and aspir
loaded with clopid
Hochholzer et al. (18) 802 1 Pre-procedural pla
with clopidogrel pr
Barragan et al. (25) 36 1 P2Y12 reactivity ra
Gurbel et al. (26) 120 1 P2Y12 reactivity ra
aggregation, and A
Ajzenberg et al. (27) 49 1 Shear-induced pla
Wong et al. (28) 264 2 Platelet inhibition
Buonamici et al. (19) 804 1 Post-treatment pla
CS  acute coronary syndrome; CAD  coronary artery disease; GP  glycoprotein; MACE  m
ercutaneous coronary intervention; STEMI  ST-segment elevation myocardial infarction; VASP-Paatients with post-treatment platelet aggregation 70% in
esponse to 10 mol/l ADP stimulation.
elation of platelet reactivity to outcomes of GP IIb/IIIa
nhibitor therapy. The GOLD (AU-Assessing Ultegra)
tudy reported a relation between inhibition of platelet
unction and MACE. The study included 500 patients
ndergoing PCI and used the VerifyNow GP IIb/IIIa assay
67). In all, 25% of patients did not achieve 95% platelet
nhibition 10 min after administration of a GP IIb/IIIa
nhibitor. These patients had a significantly higher inci-
ence of MACE (14.4% vs. 6.4% for patients with 95%
nhibition; p  0.006). In multivariate analysis, platelet
nhibition 95% 10 min after GP IIb/IIIa inhibitor admin-
stration was independently associated with a 50% lower risk
f MACE.
vidence for a threshold of post-treatment platelet reac-
ivity associated with long-term ischemic events. There
s preliminary evidence for a potential threshold of platelet
eactivity as measured by LTA after ADP stimulation that
s associated with an increased risk of post-discharge isch-
mic events after PCI. In the PREPARE POST-
TENTING (Platelet Reactivity in Patients and Recurrent
vents Post-Stenting) study, the first investigation linking
igh post-treatment platelet reactivity to ADP and the
ccurrence of post-discharge ischemic events; a threshold of
pproximately 50% periprocedural platelet aggregation in
esponse to 20 mol/l ADP was associated with the
ccurrence of ischemic events during 6-month follow-up
20). Similarly, in another study, approximately 40% platelet
o Clinical Outcomes
onsiveness to Clinical Outcomes
sults Clinical Relevance
ess; STEMI patients loaded Ischemic events (6 months)
ggregation, CAD patients Ischemic events (3 months)
aggregation, patients loaded
of elective PCI
Ischemic events (6 months)
telet aggregation; patients
t time of elective PCI 
In-hospital post-PCI myonecrosis,
inflammation marker release
ggregation; patients on
therapy pre-elective PCI
Ischemic events (12 months)
ggregation; NSTEMI ACS
pidogrel pre-PCI
Ischemic events (1 month)
responsiveness; patients
mmediately after elective PCI
In-hospital post-PCI myonecrosis
ggregation; patients treated
tive PCI
Ischemic events (1 month)
VASP-P measurement Stent thrombosis
VASP-P measurement, platelet
imulated GP IIb/IIIa expression
Stent thrombosis
ggregation Stent thrombosis
ifyNow P2Y12 assay Stent thrombosis
ggregation Stent thrombosis
verse cardiovascular events; NSTEMI  non–ST-segment elevation myocardial infarction; PCI 
sphorylated vasodilator-stimulated phosphoprotein.ess t
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Platelet Function Versus Clinical Outcomes November 6, 2007:1822–34ith the occurrence of stent thrombosis (23). In a third
tudy by the same group, a threshold of approximately 40%
re-procedural platelet aggregation in response to 5 mol/l
DP among patients receiving long-term clopidogrel and
spirin therapy before undergoing stenting was associated
ith the occurrence of ischemic events over the ensuing 12
onths (26) (Fig. 7). The latter study suggests the potential
tility of a pre-PCI platelet reactivity measurement as a
otential marker of long-term ischemic events. The timing
nd method of measuring platelet function that best corre-
ates with patient outcomes is under investigation.
The aforementioned studies might provide a “testable”
evel of post-treatment platelet reactivity in future studies,
imilar to the INR ranges established for warfarin therapy.
ur data suggest that adequate protection against ischemic
vents with aspirin and clopidogrel therapy might be
chieved by low to moderate levels of post-treatment plate-
et reactivity in the majority of patients. These findings have
mplications on bleeding risks as well during dual antiplate-
et therapy that might accompany markedly low levels of
ost-treatment platelet reactivity. Currently, the relation of
leeding to levels of ADP-induced aggregation is unknown.
uture studies will be required to determine whether there
s a therapeutic window for oral antiplatelet agents akin to
he INR used for warfarin therapy.
imitations of Focusing on
latelet Function Alone to Predict Risk
ost of the studies summarized in the preceding text
easured platelet function in isolation. None of the studies
ssessed platelet–fibrin interactions, the kinetics of throm-
in generation, or measurements of platelet–fibrin clot
trength, which could play important roles in predicting
schemic events. A recent study compared the ability of
hrombelastography measurements (maximum platelet–
brin clot strength and time to initial platelet–fibrin clot
ormation) and platelet reactivity to ADP measured by LTA
o predict ischemic events 6 months after PCI (20). Of 193
atients studied, 32% of those in the highest quartile of
DP-induced aggregation had an ischemic event by 6
onths versus 10% of patients in the lowest quartile (p 
.02). When stratified by platelet–fibrin clot strength, 58%
f patients in the highest quartile had an ischemic event by
months versus only 2% of patients in the lowest quartile (p
0.001) (20). Methods that measure coagulation and
latelet interactions might prove to be better predictive tools
han isolated measurements of platelet function.
onclusions
he measurement of platelet function and response to
harmacological antagonists is inherently complex and con-
ounded by several methodological factors, making it diffi-
ult to correlate results with clinical outcomes and, in turn,
o use the results to guide therapy. A major limitation that
as hampered both knowledge acquisition and translation to rhe clinical arena is the absence of established investigative
latforms and trials of sufficient size to either support or
Figure 7 Cumulative Frequency Distributions of ADP-Induced
Platelet Aggregation in Relation to Clinical Outcomes
(A) Distributions measured in patients with and without stent thrombosis. Data
from Gurbel et al. (26). (B) Distributions measured in patients with and without
ischemic events within 6 months of elective coronary-artery stenting; after percuta-
neous coronary intervention (PCI) measurement. Data from Gurbel et al. (20). (C)
Distributions measured in patients with and without ischemic events within 1 year
treated with clopidogrel therapy before elective coronary artery stenting; before PCI
measurement. Data from Bliden et al. (23). ADP  adenosine diphosphate; ST 
stent thrombosis.efute hypothesis-generating observations from small stud-
i
p
t
b
o
R
D
R
b
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
1833JACC Vol. 50, No. 19, 2007 Gurbel et al.
November 6, 2007:1822–34 Platelet Function Versus Clinical Outcomeses. The clinical trials community, working closely with
latelet biologists, clinician-scientists, and the pharmaceu-
ical and device industries, must formulate an agenda,
uilding on the strengths of collaboration to address an area
f unmet clinical need.
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